Matthew is the President of FENIX Group International. He is a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006​. Regular attendance at large and small CV/MET scientific meetings​. Architect of novel methods for assessing market opportunities.​ Matthew's areas of expertise include market landscaping / thought leadership​, life sciences consulting / business intelligence. Matthew regualrly contributes Diabetes therapy area leadership in insulin, incretin therapies, novel MOAs, and diabetes devices.​​